Novartis Buys Alnylam Stock for Nearly $1M

The transaction allows Novartis to maintain its roughly 13.4 percent equity stake in the RNAi drug developer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.